[go: up one dir, main page]

UY30404A1 - NEW CRYSTAL FORMS OF ACID (TRANS-4- {4 - [({5 - [(3,4-DIFLUOROPHENYL) AMINO] -1,3,4-OXADIAZOL-2-IL} CARBONYL) AMINO] PHENYL} CILOHEXIL) ACETIC , COMPOSITIONS AND APPLICATIONS - Google Patents

NEW CRYSTAL FORMS OF ACID (TRANS-4- {4 - [({5 - [(3,4-DIFLUOROPHENYL) AMINO] -1,3,4-OXADIAZOL-2-IL} CARBONYL) AMINO] PHENYL} CILOHEXIL) ACETIC , COMPOSITIONS AND APPLICATIONS

Info

Publication number
UY30404A1
UY30404A1 UY30404A UY30404A UY30404A1 UY 30404 A1 UY30404 A1 UY 30404A1 UY 30404 A UY30404 A UY 30404A UY 30404 A UY30404 A UY 30404A UY 30404 A1 UY30404 A1 UY 30404A1
Authority
UY
Uruguay
Prior art keywords
amino
oxadiazol
difluorophenyl
trans
carbonyl
Prior art date
Application number
UY30404A
Other languages
Spanish (es)
Inventor
Andrew Hornby Dobson
Original Assignee
Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca filed Critical Astrazeneca
Publication of UY30404A1 publication Critical patent/UY30404A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Se proporcionan formas cristalinas novedosas del compuesto ácido (trans-4-{4-[ ({5-[ (3,4-difluorofenil)amino]-1,3,4-oxadiazol-2-il}carbonil)amino]fenil}ciclohexil)acético, junto con procesos para la fabricacion de dichas formas, composiciones farmacéuticas que las comprenden y el uso de dichas formas en tratamiento médico.Novel crystalline forms of the acid compound (trans-4- {4- [({5- [(3,4-difluorophenyl) amino] -1,3,4-oxadiazol-2-yl} carbonyl) amino] phenyl} are provided cyclohexyl) acetic, together with processes for the manufacture of said forms, pharmaceutical compositions comprising them and the use of said forms in medical treatment.

UY30404A 2006-06-12 2007-06-11 NEW CRYSTAL FORMS OF ACID (TRANS-4- {4 - [({5 - [(3,4-DIFLUOROPHENYL) AMINO] -1,3,4-OXADIAZOL-2-IL} CARBONYL) AMINO] PHENYL} CILOHEXIL) ACETIC , COMPOSITIONS AND APPLICATIONS UY30404A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0611552.1A GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds

Publications (1)

Publication Number Publication Date
UY30404A1 true UY30404A1 (en) 2008-01-31

Family

ID=36745696

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30404A UY30404A1 (en) 2006-06-12 2007-06-11 NEW CRYSTAL FORMS OF ACID (TRANS-4- {4 - [({5 - [(3,4-DIFLUOROPHENYL) AMINO] -1,3,4-OXADIAZOL-2-IL} CARBONYL) AMINO] PHENYL} CILOHEXIL) ACETIC , COMPOSITIONS AND APPLICATIONS

Country Status (16)

Country Link
EP (1) EP2041101A1 (en)
JP (1) JP2009539954A (en)
KR (1) KR20090015980A (en)
CN (1) CN101466690A (en)
AR (1) AR061332A1 (en)
AU (1) AU2007259031A1 (en)
BR (1) BRPI0712354A2 (en)
CA (1) CA2653550A1 (en)
CL (1) CL2007001700A1 (en)
GB (1) GB0611552D0 (en)
IL (1) IL195348A0 (en)
MX (1) MX2008015762A (en)
NO (1) NO20084963L (en)
TW (1) TW200815378A (en)
UY (1) UY30404A1 (en)
WO (1) WO2007144571A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064189A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
EP1966221A1 (en) 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
CN101460470B (en) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 1,3,4-oxadiazole derivatives as DGAT1 inhibitors
EP2041100B1 (en) 2006-05-30 2010-12-22 AstraZeneca AB Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
EP2120911A1 (en) * 2007-02-15 2009-11-25 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
AR066169A1 (en) 2007-09-28 2009-07-29 Novartis Ag DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT
KR20100099738A (en) 2007-12-20 2010-09-13 아스트라제네카 아베 Carbamoyl compounds as dgat1 inhibitors 190
DK3366686T3 (en) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc INHIBITORS OF DIACYLGLYCEROL-O-ACYLTRANSFERASE 1 (DGAT-1) AND USES THEREOF
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
FR2963005B1 (en) * 2010-07-23 2012-08-17 Sanofi Aventis DERIVATIVES OF OXADIAZOLES AND PYRIDAZINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044152A1 (en) * 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
WO2006064189A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors

Also Published As

Publication number Publication date
JP2009539954A (en) 2009-11-19
KR20090015980A (en) 2009-02-12
TW200815378A (en) 2008-04-01
IL195348A0 (en) 2009-08-03
AU2007259031A1 (en) 2007-12-21
BRPI0712354A2 (en) 2012-06-05
CL2007001700A1 (en) 2008-01-18
WO2007144571A1 (en) 2007-12-21
CA2653550A1 (en) 2007-12-21
MX2008015762A (en) 2009-03-16
AR061332A1 (en) 2008-08-20
CN101466690A (en) 2009-06-24
NO20084963L (en) 2009-01-07
GB0611552D0 (en) 2006-07-19
EP2041101A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
UY30404A1 (en) NEW CRYSTAL FORMS OF ACID (TRANS-4- {4 - [({5 - [(3,4-DIFLUOROPHENYL) AMINO] -1,3,4-OXADIAZOL-2-IL} CARBONYL) AMINO] PHENYL} CILOHEXIL) ACETIC , COMPOSITIONS AND APPLICATIONS
UY29384A1 (en) ACID DERIVATIVES 2-3S, 4R) -4 - (((3,4-DICLORO-5-METHYL-1H-PIRROL-2-IL) CARBONIL) AMINO) -1,3-TIAZOL-5-CARBOXYL AND ITS SALTS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS.
ECSP088358A (en) TREATMENT AND PROPHYLAXIS OF MICROANGIOPATHIES
CL2007003805A1 (en) CRYSTAL FORM OF COMPOUND 3 - {[5- (ACETIDIN-1-ILCARBONIL) PIRACIN-2-IL] OXI} -5 - [(1-METHYLETY) OXI] -N-1H-PIRAZOL-3-ILBENZAMIDA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES IN THIS FORM; AND USE FOR DIABETE TREATMENT
CL2008002998A1 (en) Piperazine-1-carboxamide derived compounds, faah inhibitor; pharmaceutical composition comprising said compound; and use of the compound for the treatment of inflammatory or neuropathic pain, anxiety and depression.
CL2011001224A1 (en) Compounds derived from benzofuran-3-carboxamide; pharmaceutical composition that includes them; and its use in hepatitis C virus treatment.
UY30544A1 (en) PIRROLO-PIPERIDINE COMPOUNDS AND PHARMACEUTICAL SALTS ACCEPTABLE OF THE SAME, MANUFACTURING PROCESSES, COMPOSITIONS AND APPLICATIONS
UY32259A (en) NEW HYDROXYARENE COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND APPLICATIONS
UY28747A1 (en) NEW PROCESS FOR SYNTHESIS AND NEW CRYSTAL FORM OF AGOMELATINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20120345A1 (en) DERIVATIVES OF 2- (1H-PIRROLO [2,3-B] PYRIDIN-5-ILOXI) -N-FENYLSULFONYLBENZAMIDE AS INHIBITORS OF ANTI-APOPTOTIC PROTEINS
UY32462A (en) NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT
NI201000079A (en) SOME DERIVATIVES OF 2-PIRAZINONE AND THEIR USE AS INHIBITORS OF NEUTROPHILES ELASTASE.
CL2008002227A1 (en) Substituted 4 - [(8r) -4-amino-5-oxo-7,8-dihydrorimido [5,4-f] [1,4] oxazepin-6 (5h) -yl] phenyl derivative compounds; its pharmaceutical composition; and use of the compounds in the treatment of type 2 diabetes, particularly useful for treating obesity.
AR081760A1 (en) A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES ACID 3- (6- (1- (2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPANCARBOXAMIDE) -3-METHYLPIRIDIN-2-IL) BENZOIC, A METHOD TO PRODUCE THE SAME, A TABLET AND A UNITARY FORM OF ORAL DOSAGE THAT INCLUDES IT AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
CL2008001821A1 (en) Imidazo [2,1-b] -thiazole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of diabetes, metabolic syndrome, insulin resistance, among others.
CL2009000004A1 (en) Crystal form of r-2- (4-cyclopropanesulfonyl-phenyl) -n-pyrazin-2-yl-3- (tetrahydropyran-4-yl) -propionamide; pharmaceutical composition comprising said crystalline form; and use for the treatment of diabetes or hyperglycemia.
CL2007002967A1 (en) CRYSTAL FORM A OF THE COMPOUND 4- [3- (4-CYCLOPROPANCARBONIL-PIPERAZIN-1-CARBONIL) -4-FLUORO-BENCIL] -2H-FTALAZIN-1-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF A
SV2008003088A (en) NEW CRYSTAL FORM VI OF AGOMELATINE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CL2011003138A1 (en) N- (protected- n- (3-methoxy-5-methylpyrazon-2-yl) -2- (4- [1,3,4-oxadiazol-2-yl] phenyl) pyridine-3-sulfonamide and its process of preparation.
EA200870103A1 (en) PHENOXYACIC ACIDS AS PPAR DELTA ACTIVATORS
CL2008003576A1 (en) 6,7-dihydro-5h-imidazo [1,2-alpha] imidazole-3-carboxylic acid amide derivative compounds; pharmaceutical composition comprising them; and uses in the treatment of an inflammatory condition.
MX2010003224A (en) Biaryl sulfonamide derivatives.
CL2011001098A1 (en) Compounds derived from 4-fluoro-1h-isoindol-3-amine; b-secretase (bace) inhibitors; pharmaceutical composition; and its use for the treatment or prevention of a pathology related to beta amyloid protein such as down syndrome, Alzheimer's, senile dementia and dementia associated with parkinson's, among others.
CL2008002247A1 (en) Compounds derived from phenyl amide; Preparation process; pharmaceutical composition containing them; and its use in the preparation of drugs for the treatment of sleep disorders, narcolepsy and psychiatric disorders, among others.
UY30214A1 (en) MODIFICATIONS OF (5S) -5- (4- (5-CHLORINE-PIRIDIN - 2-ILOXI) -PIPERIDINA-1-SULFONILMETIL) -5-METHYL-IMIDAZOLIDINE-2,4-DIONA, PROCESSES FOR PREPARATION, COMPOSITIONS THAT THE CONTAIN AND APPLICATIONS.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170627